End Stage COPD Guidance Document

Size: px
Start display at page:

Download "End Stage COPD Guidance Document"

Transcription

1 End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for hospice services: The patient has all of the following: Disabling dyspnea at rest or with minimal exertion Little or no response to bronchodilators Decreased functional capacity (e.g. bed to chair existence, fatigue and cough) AND Progression of disease as evidenced by a recent history of increasing physician office or emergency visits and/or hospitalizations for pulmonary infection and/or respiratory failure. Documentation within the past 3 months of one or more of the following: Hypoxemia at rest on room air (p02 55 mmhg by ABG) or oxygen saturation 88% or Hypercapnia evidenced by pco2 50 mmhg Note: A serial decrease of FEVI > 40 ml/yr is objective evidence for disease progression but is not required Supporting documentation includes: Cor pulmonale and right heart failure secondary to pulmonary disease (e.g. not secondary to the left heart disease or valvulopathy) Unintentional progressive weight loss > 10% of body weight over the preceding six months Resting tachycardia > 100 bpm In the absence of one or more of the above criteria, rapid decline or co morbidities may also support the physician s determination of a life expectancy of less than 6 months and eligibility for hospice care. Palliative Dyspnea Management Low doses of short acting opioids are the mainstays of palliative dyspnea management in end stage COPD. In addition, because of the extreme anxiety that can accompany the sensation of dyspnea, low dose benzodiazepines may also be useful. The goal is not to lower the respiratory rate, but to reduce the patient s sensation of breathlessness and any associated anxiety. The following initial doses are recommended for opioid naïve patients: Morphine 2.5mg PO/SL every 2 hours as needed for dyspnea Lorazepam 0.25mg PO/SL every 4 hours as needed for dyspnea associated anxiety Non Pharmacological Management Providing an over the bed table will help patients who are bedbound position themselves with their head up; this allows support from their elbows and arms to lengthen and expand the chest cavity (tripoding). Cool air, avoid closed in spaces, minimize odors, and provide visual signs of air movement such as ribbons tied to fans to help reduce the patient s sense of suffocation. Psychosocial, emotional and spiritual support is extremely helpful in reducing fear, anxiety, and depression. Oxygen therapy should be considered for any patient with hypoxemia and during periods of exacerbation. Clinical Pearls In general, patients with end stage COPD no longer have the ability to use inhalers correctly due to lack of breath control. Administering medications using a nebulizer does not require additional breathing effort from the patient. Also, nebulized medications do not require patients to coordinate activation of device and inspiratory breath, or to hold breath while waiting for the inhaled medication to deposit in the lungs. This makes for a more effective and efficient route of administration. Oral corticosteroids, such as prednisone or dexamethasone, may be more effective than inhaled corticosteroids. Oral corticosteroids can also palliate associated symptoms by increasing appetite and helping with fatigue. Low, non sedating doses of benzodiazepines, such as lorazepam, scheduled around the clock (ATC) and on an as needed (PRN) basis will help reduce the anxiety component which can exacerbate the sensation of dyspnea. Normal saline via nebulizer, offered as frequently as the patient would like, provides moisture to the airways and gives the individual the feeling that they are doing something to help with breathing. Patients who have end stage pulmonary disease should receive the seasonal influenza vaccine. Evaluate patient ability to use inhalers, both metered dose (MDI) and dry powder (DPI), for both lung capacity, cognitive and physical ability to coordinate inhalation with inhaler activation (see chart next page). Convert patients not able to demonstrate proper technique on a routine basis to nebulized treatments for improved medication delivery. 2013, HospiScript Services druginformation@hospiscript.com tel: fax:

2 End Stage COPD Guidance Document Appropriate medication use at end of life: As the patient s medication profile is reviewed, the hospice clinician can assist the patient and family in decision making about which medications are providing benefit and contributing to quality of life. The clinician must also be alert to medications that may be contributing to problematic symptoms, causing adverse effects, or simply no longer have a beneficial role at end of life. The interdisciplinary team (IDT) can serve as a resource for the clinician who is not experienced or confident in discussing medication appropriateness. The team meeting is one opportunity for learning from team members including nurses, pharmacists and physicians. Clinicians who do not attend team meetings, such as admissions or on call staff, must be intentional in seeking the input and expertise of these co workers. Knowledge sharing about appropriate medication use happens between clinicians, hospice team members, and patient or family. This process facilitates informed decisions about medication use that is driven by the patient s goals of care and evidenced based medicine. The BUILD Model: In hospice, BUILDing the plan of care with the patient, family, and the IDT is the key to success. The BUILD model provides a framework for members of the hospice IDT to facilitate discussions of medication appropriateness. Talking points are incorporated into the BUILD model to spark conversations with the patient or family regarding the appropriate use of medications. B=Build a foundation of trust and respect GOAL: Affirm the patient and caregiver; listen more than you talk. Validate their efforts and concerns. This is an opportunity to gain insights into cultural norms, spiritual practices and family dynamics. U=Understand what the patient knows about the medication GOAL: By asking open ended questions, facilitate the patient and caregiver in drawing their own conclusions that the medicine may no longer be effective OR at some point will no longer be effective. Understanding what the patient knows about a medication, or what he/she expects from it, will allow the hospice clinician to provide individualized, evidence based information regarding the medication and how it impacts the disease process. Address worry as it will be a barrier in decision making. I=Inform the patient of evidenced based information regarding the medication GOAL: Provide evidence based information in a neutral manner by bridging medical terminology and reasoning to the patient level. L=Listen to the patient s goals and expectations GOAL: Learn what is important to the patient/family. It is important to take information the patient has shared about why he/she takes the medication and relate that to his/her goals and expectations. If the patient is struggling with making a change it may be helpful to share experiences. Many patients feel they are losing control. Re assuring patients about the importance of their participation in decision making can go a long way in keeping conversations open. For those situations where the patient is unable to participate in the discussion or decision making, the patient s wishes should still be the focus, and not the wishes of the decisionmaker, which may be different than the patient s. D=Develop a plan of care in collaboration with the patient, family and interdisciplinary team GOAL: Being part of the process empowers the patient and caregiver and increases compliance with the plan. The patient and caregiver must realize they DO have choices. Work as a team for the benefit of the patient. Goals need to be patient centered and measurable. Focus on patient comfort and what enhances quality of life. Include acknowledgement that the patient s physician continues to provide input about these decisions. Once the plan has been developed, ask the patient for feedback regarding the plan and make adjustments if needed. This demonstrates your interest in meeting them where they are in this process and that their input has value. Revisiting the topic on an ongoing basis is often necessary; let the patient know changes are part of this process. Assessing the Patient s Ability to Use Inhalers Dry Powder Inhaler (DPI) Metered Dose Inhaler (MDI) For efficient use, patient must be able to: For efficient use, patient must be able to: 1. Follow instructions to prepare specific DPI device for use (e.g., Diskus, Flexhaler, Twisthaler ) 1. Follow instructions to prepare specific MDI device for use (e.g., traditional MDI, Respimat ) 2. Turn head away from device to exhale completely 2. Shake inhaler, if appropriate, and hold properly 3. Close mouth around mouthpiece 3. Position for open airway inhalation 4. Inhale forcefully, steadily, and deeply to propel medicated 4. Exhale completely powder into lungs 5. Close mouth around device mouthpiece 5. Hold breath for 10 seconds 6. Activate inhaler device timed to start of inspiration 6. Remove DPI from mouth and exhale slowly 7. Slowly and deeply inhale medication over 5 7 seconds 7. Repeat steps 1 6 if more than 1 inhalation is prescribed 8. Hold breath for 10 seconds 9. Wait 1 minute and repeat steps 2 8 if more than 1 inhalation is ordered See Complete COPD Toolkit for reference list 2013, HospiScript Services druginformation@hospiscript.com tel: fax:

3 COPD and Asthma Medications Generic Brand Dosage Forms Available FDA Approved Indication 1 Generic Available? Average AWP/Month ANTICHOLINERGICS (Short Acting, SAMA) provide bronchodilation by inhibiting acetylcholine at parasympathetic sites in bronchial smooth muscle Ipratropium Atrovent Nebulizer, Aerosol inhaler COPD Yes (neb) $240 HFA / $48 Neb ANTICHOLINERGICS (Long Acting, LAMA) provide bronchodilation by inhibiting acetylcholine at type 3 muscarinic (M 3 ) receptors Aclidinium Tudorza Pressair Powder inhaler COPD No $261 DPI Tiotropium Spiriva Powder capsule inhaler COPD No $312 DPI BETA 2 AGONISTS (Short Acting, SABA) relax airway smooth muscle (bronchodilation) by stimulating beta 2 receptors Albuterol AccuNeb, Ventolin, Proair Nebulizer, Aerosol inhaler Asthma/ COPD Yes $45 HFA / $20 Neb Levalbuterol Xopenex Nebulizer, Aerosol inhaler Asthma Yes (neb) $105 HFA / $458 Neb Metaproterenol Alupent Tablets, Syrup Asthma/ COPD Yes $140 tabs Pirbuterol Maxair Autohaler Aerosol inhaler Asthma No $490 MDI Terbutaline Terbutaline Tablets Asthma Yes $63 tabs BETA 2 AGONISTS (Long Acting, LABA) relax airway smooth muscle (bronchodilation) by stimulating beta 2 receptors Arformoterol Brovana Nebulizer COPD No $517 Neb Formoterol Foradil Aerolizer, Perforomist Nebulizer, Powder inhaler Asthma/COPD No $510 Neb / $215 DPI Indacaterol Arcapta Powder inhaler COPD No $210 DPI (capsules) Salmeterol Serevent Powder inhaler Asthma/COPD No $222 MDI INHALED CORTICOSTEROIDS (ICS) control inflammation with slightly varying specific mechanisms most work by decreasing leukocyte migration and capillary permeability while increasing cellular lysosomal stabilization Beclomethasone 2 QVAR Aerosol inhaler Asthma No $170 MDI Budesonide Pulmicort Nebulizer, Powder inhaler Asthma Yes (neb) $500 Neb / $183 DPI Ciclesonide Alvesco Aerosol inhaler Asthma No $209 MDI Flunisolide 2 Aerospan (formerly AeroBid) Aerosol inhaler Asthma No Available Fall 2013 Fluticasone 2 Flovent Aerosol inhaler, Powder inh. Asthma No $301 HFA / $150 DPI Mometasone Asmanex Aerosol inhaler Asthma No $180 MDI LEUKOTRIENE MODIFIERS help control inflammation, inhibit bronchoconstriction, and decrease airway edema by inhibiting leukotriene receptors Montelukast Singulair Tablets, granules Asthma Yes $170 tabs/ $340 gran Zafirlukast Accolate Tablets Asthma Yes $107 tabs MAST CELL STABILIZERS decrease inflammation by preventing activation of many inflammatory mediators including mast cell release of histamine and leukotrienes Cromolyn 2 Cromolyn Nebulizer Asthma Yes $120 Neb 2013, HospiScript Services druginformation@hospiscript.com tel: fax:

4 COPD and Asthma Medications Generic Name Brand Name Dosage Forms Available FDA Approved Indication 1 Generic Available? COMBINATION combine two medications with different mechanisms of action (found above) Budesonide/ Formoterol Fluticasone/ Salmeterol Fluticasone/ Vilanterol Ipratropium/ Albuterol Mometasone/ Formoterol Symbicort Aerosol inhaler Asthma/ COPD No $280 MDI Average AWP/Month Advair HFA, Advair Diskus Aerosol inhaler, Powder inhaler Asthma/COPD No $375 HFA / $305 DPI Breo Ellipta Powder inhaler COPD No Available Fall 2013 Combivent Respimat, DuoNeb Nebulizer, Aerosol inhaler Asthma/COPD Yes (neb) $288 MDI / $90 Neb Dulera Aerosol inhaler Asthma No $235 MDI OTHER result in bronchodilation believed to be the result of inhibiting phosphodiesterase III and IV Roflumilast Daliresp Tablets COPD No $210 tabs Theophylline Theo Dur Tablets, Elixir Asthma/COPD Yes $40 tabs / $111 elixir 1 The FDA approved indications are listed but some of the medications are additionally used off label for either COPD or Asthma 2 These medications also available in intranasal forms indicated for allergic rhinitis: beclomethasone (Beconase AQ ), fluticasone (Flonase ), cromolyn (NasalCrom OTC) DPI = dry powder inhaler MDI = metered dose inhaler HFA = hydrofluoroalkane propellant (chlorofluorocarbon/cfc replacement) AWP= average wholesale price In compliance with a rule about ozone depleting substances, the FDA has announced that 7 available asthma and chronic obstructive pulmonary disease (COPD) metered dose inhalers that use CFCs as propellants are being removed from the marketplace. The affected products and their phase out dates are as follows: nedocromil (Tilade Inhaler, King Pharmaceuticals), June 14, 2010 metaproterenol (Alupent Inhalation Aerosol, Boehringer Ingelheim), June 14, 2010 triamcinolone (Azmacort Inhalation Aerosol, Abbott Laboratories), December 31, 2010 cromolyn (Intal Inhaler, King Pharmaceuticals), December 31, 2010 flunisolide (Aerobid Inhaler System, Forest Laboratories), June 30, 2011; to be replaced with Aerospan Fall 2013 ipratropium and albuterol in combination (Combivent Inhalation Aerosol, Boehringer Ingelheim Pharmaceuticals), December 31, 2013; to be replaced with Combivent Respimat mid pirbuterol (Maxair Autohaler, Graceway Pharmaceuticals), December 31, 2013 References: Lexi Comp Online [Internet database]. Lexi Drugs Online, Hudson, Ohio: Lexi Comp, Inc. Accessed August 20, 2013 Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Accessed 2/18/2013 Hitt E. FDA announces phase out of CFC based asthma and COPD inhalers. Medscape Medical News, April 16, Available at: , HospiScript Services druginformation@hospiscript.com tel: fax:

5 COPD Inhaler Decision Algorithm Patient PPS 40% AND/OR Poor Inhaler Technique Assess & document patient s function and ability to use inhalers: 1. On admission to hospice 2. With any exacerbation of condition 3. With a decline in status 4. At every recertification 5. Prior to ordering inhaler refills 6. With every change in location (transfer to/from ECF, IPU, etc) Patient Function PPS 40% AND/OR Patient unable to use inhalers correctly** STEP 1: Assess for adverse effects (AE) Review medication profile and address AE resulting from exposure to polypharmacy and/or incorrect use.** Common AE from incorrect use of inhalers: Beta-agonists: anxiety, tachycardia, tremor ICS: oral thrush, pharyngitis Anticholinergics: dry mouth, urinary retention NO Acute Symptom Management Needed? YES STEP 2: Eliminate duplications Review medication profile and eliminate duplications of therapy. Removing duplications also reduces AE exposure risk. See Inhaler Component Matrix for guidance. Common duplications include: Multiple beta-agonists: scheduled short and long-acting inhalers Multiple corticosteroids: oral and ICS Multiple anticholinergics: oral and inhaled anticholinergics GOAL: Discontinue ineffective inhalers while maintaining symptom control. Prioritize approach based on patient assessment and goals.** Optimize therapy to minimize risk of COPD exacerbations. Assess therapy to determine medication problems and set priorities for change. Ideal therapy for most patients with ES COPD will include nebulized albuterol +/- ipratropium and an oral corticosteroid. Provide benzodiazepine and opioid as needed for dyspnea symptom management. 1. Manage symptoms per Dyspnea GEMS** 2. Re-assess patient function to optimize therapy 3. Develop proactive plan of care to avoid recurrence TARGET ASSESS PLAN Optimize therapy: Treat adverse effects Discontinue inhalers Initiate nebulizers Eliminate duplications OPTION Patient or HCP resistant to medication changes? Continue therapy. Monitor patient for symptom control and AE. Assess & document patient s function and treatment plan. Consult BUILD Model for discussion points** ** additional information provided in supporting text Abbreviations: AE = adverse effects, GEMS = guidelines for effective management of symptoms, HCP = health care provider, ICS = inhaled corticosteroid, LABA = long acting beta agonist, LAMA = long acting muscarinic antagonist, SABA = short acting beta agonist, SAMA = short acting muscarinic antagonist 2013, HospiScript Services

6 Inhaler Component Matrix: Determining Therapy Duplications Therapeutic Class aclidinium (Tudorza) albuterol (Proair, Ventolin, Proventil) beclomethasone (QVAR) budesonide (Pulmicort) ciclesonide (Alvesco) flunisolide (Aerospan) Medication (Brand): Inhalers fluticasone (Flovent) formorterol budesonide (Symbicort) formoterol (Foradil) formoterol mometasone (Dulera) indacaterol (Arcapta) ipratropium (Atrovent) ipratropium albuterol (Combivent) levalbuterol (Xopenex) pirbuterol (Maxair) mometasone (Asmanex) salmeterol (Serevent) Beta Agonist, Short Acting (SABA) X X X X Beta Agonist, Long Acting (LABA) X* X X X X X* X* X* X X Anticholinergic, Short Acting (SAMA) X* X* (LAMA) X X Corticosteroid X X X X X X X X X Anticholinergic, Long Acting Inhalers X = indicates inhaler or nebulizer component X* = when scheduled, short acting agents (SABA & SAMA) are therapeutic duplications with long acting agents (LABA or LAMA) salmeterol fluticasone (Advair) tiotropium (Spiriva) Therapeutic Class Beta Agonist, Short Acting albuterol (Accuneb) arformoterol (Brovana) budesonide (Pulmicort) formoterol (Perforomist) Medication (Brand): Nebulizers & Orals ipratropium (Atrovent) ipratropium albuterol (Duoneb) levalbuterol (Xopenex) dexamethasone (Decadron) methylprednisolone (Medrol) montelukast (Singulair) roflumilast (Daliresp) prednisone (Deltasone) (SABA) X X X* O Beta Agonist, Long Acting theophylline (Theo 24) zafirlukast (Xolair) Therapeutic Targets: Ideal therapy for most patients with ES COPD will include nebulized albuterol +/ ipratropium and an oral corticosteroid. Provide benzodiazepine and opioid as needed for dyspnea symptom management. Control symptoms (LABA) X* X X X* X* O Avoid adverse events Anticholinergic, Short Acting (SAMA) X X Reduce polypharmacy Corticosteroid X X O O X O O Nebulizers Oral X = indicates inhaler or nebulizer component X* = when scheduled, short acting agents (SABA) are therapeutic duplications with long acting agents (LABA) O = indicates oral medication with same or similar therapeutic action to inhaler or nebulizer component Note: there are currently no LAMA agents with a nebulizer dosage form on the market in the US = indicates ideal therapy for most patients (nebulized beta agonist +/ anticholinergic and oral corticosteroid) (c) 2013, HospiScript Services druginformation@hospiscript.com tel: fax:

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung

More information

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Foundations of Pharmacology

Foundations of Pharmacology Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids

More information

Medications Affecting The Respiratory System

Medications Affecting The Respiratory System Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency

More information

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the

More information

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

STRIVERDI RESPIMAT (olodaterol hcl) aerosol STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

MDI Bonanza. Dwayne Griffin, DO

MDI Bonanza. Dwayne Griffin, DO MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing

More information

Select Inhaled Respiratory Agents

Select Inhaled Respiratory Agents Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints

More information

Common Inhaled Asthma Medications Dose Comparison and Tips for Use

Common Inhaled Asthma Medications Dose Comparison and Tips for Use Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications

More information

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

Learning Objectives 4/26/2012. Review normal lung function and COPD pathophysiology Discuss pharmacological management

Learning Objectives 4/26/2012. Review normal lung function and COPD pathophysiology Discuss pharmacological management Marliese Gibson PharmD HospiScript, a Catalyst Rx Company May 16, 2012 Chronic Obstructive Pulmonary Disease Learning Objectives Review normal lung function and COPD pathophysiology Discuss pharmacological

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Asthma/COPD Update with Inhaler Workshop

Asthma/COPD Update with Inhaler Workshop Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting

More information

FASENRA (benralizumab)

FASENRA (benralizumab) FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Respiratory Medications and Devices Update 2/15

Respiratory Medications and Devices Update 2/15 Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN

Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Goals of Therapy Asthma Prevent symptoms COPD Reduce COPD symptoms Decrease use of SABAs Maintain normal pulm function & prevent loss

More information

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly

More information

Key features and changes to these four components of asthma care include:

Key features and changes to these four components of asthma care include: Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

MANAGING ASTHMA. Nancy Davis, RRT, AE-C MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma

More information

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial

More information

Diagnosis and Management of Asthma

Diagnosis and Management of Asthma Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:

More information

Provider Respiratory Inservice

Provider Respiratory Inservice Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines

More information

Asthma. Definition. Symptoms

Asthma. Definition. Symptoms Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some

More information

Nancy Davis, RRT, AE-C

Nancy Davis, RRT, AE-C Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Reference Guide for Caring for Pediatric Patients with Asthma

Reference Guide for Caring for Pediatric Patients with Asthma Reference Guide for Caring for Pediatric Patients with Asthma Co-Chair: Nancy Cantey Banasiak, DNP, PPCNP-BC, APRN Co-Chair: Deborah Hickman, DNP, APRN-CNP, CPNP-PC, NNP-BC Asthma and Allergy SIG Members

More information

Improving Outcomes in COPD

Improving Outcomes in COPD Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea

More information

Asthma COPD Update 2018

Asthma COPD Update 2018 Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State

More information

Correct Use of Inhaler Devices

Correct Use of Inhaler Devices PL Detail-Document #300206 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Correct Use of

More information

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component

ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate

More information

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives. Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate

More information

Respiratory Health. Asthma and COPD

Respiratory Health. Asthma and COPD Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory

More information

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules

More information

10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C

10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines

More information

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,

More information

Your Inhaler Devices & You

Your Inhaler Devices & You 1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE

More information

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

reslizumab (Cinqair )

reslizumab (Cinqair ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Methacholine Challenge Test

Methacholine Challenge Test PATIENT & CAREGIVER EDUCATION Methacholine Challenge Test This information will help you prepare for your methacholine challeng e test at Memorial Sloan Kettering (MSK). A methacholine (meth-a-kole-leen)

More information

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy

More information

COPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed?

COPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed? Understanding COPD The Mount Sinai National Jewish Health Respiratory Institute was formed by the nation s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy

More information

Proposed Preferred Drug List. Clinical Criteria

Proposed Preferred Drug List. Clinical Criteria Proposed Preferred Drug List with Clinical Criteria Proposal for TennCare February 7, 2008 Page 1 of 87 PDL Decision Process The primary clinical decision that needs to be made is determining if the drugs

More information

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power

More information

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going

More information

Women Beware-The Threat of COPD

Women Beware-The Threat of COPD Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed

More information

How to Use Inhaled Medications for Asthma and COPD

How to Use Inhaled Medications for Asthma and COPD How to Use Inhaled Medications for Asthma and COPD This information is not intended to diagnose health problems or to take the place of medical advice or care you receive from your physician or other health

More information

Prescribing guidelines: Management of COPD in Primary Care

Prescribing guidelines: Management of COPD in Primary Care Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish

More information

Hospice High Dollar Medications and Possible Alternatives

Hospice High Dollar Medications and Possible Alternatives Hospice High Dollar Medications and Possible Alternatives Ly M. Dang, PharmD LDang@HospicePharmacySolutions.com Director of Pharmacy Operations Hospice Pharmacy Solutions Topics of Discussion Hospice Coverage

More information

Women Beware The Threat of COPD

Women Beware The Threat of COPD Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education

More information

benralizumab (Fasenra )

benralizumab (Fasenra ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample

More information

ASTHMA IN THE PEDIATRIC POPULATION

ASTHMA IN THE PEDIATRIC POPULATION ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center

More information

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical

More information

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Commissioner for the Department for Medicaid Services Selections for Preferred Products Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for

More information

Asthma/COPD Update with Inhaler Workshop

Asthma/COPD Update with Inhaler Workshop Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary

Three s Company - The role of triple therapy in chronic obstructive pulmonary Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov

More information

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor

More information

Advanced Pharmacology Respiratory Pharmacology

Advanced Pharmacology Respiratory Pharmacology Advanced Pharmacology Respiratory Pharmacology Thomas W. Barkley, Jr., PhD, ACNP BC, FAANP President, Barkley & Associates www.npcourses.com and Professor of Nursing Director of Nurse Practitioner Programs

More information

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR) Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of

More information

Breath of Fresh Air. nniversary 20th. New National Asthma Survey: How Does Your Asthma Compare? Long-Acting Bronchodilators: Why All the Fuss?

Breath of Fresh Air. nniversary 20th. New National Asthma Survey: How Does Your Asthma Compare? Long-Acting Bronchodilators: Why All the Fuss? Information, news and advice for improving asthma well-being Volume 12, No. 1 Summer 2010 New National Asthma Survey: How Does Your Asthma Compare? nniversary 20th Sometimes if one has to live with a chronic

More information

The Latest Medications A Pharmacological Update for RTs

The Latest Medications A Pharmacological Update for RTs The Latest Medications A Pharmacological Update for RTs Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Georgia State University Objectives

More information

Inhaled Corticosteroid Dose Comparison in Asthma

Inhaled Corticosteroid Dose Comparison in Asthma This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides

More information

Objectives. Speaker has no relationship to disclose. Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis,

Objectives. Speaker has no relationship to disclose. Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis, Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis, and COPD Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates Objectives Evaluation of medications,

More information

4/3/2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018

4/3/2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018 Approach to treatment List of medication Abbreviations When to use medications Pharmokinetics Pharmacodynamics Step wise therapy both for acute and chronic

More information

continuing education for pharmacists

continuing education for pharmacists continuing education for pharmacists Volume XXXIV, No. 12 Asthma: Approaches to Treatment and New Therapies Cortney M. Mospan, PharmD, BCACP, CGP, Assistant Professor of Pharmacy, Wingate University School

More information

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol) Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:

More information

Staying Healthy. with Asthma. Illustrations by paulsharp.com

Staying Healthy. with Asthma. Illustrations by paulsharp.com Staying Healthy with Asthma Illustrations by paulsharp.com Lungs & Asthma What is Asthma? Inflammation or swelling of airways that leads to: 1) Mucous production deep inside the airways. 2) Temporary difficulty

More information

Assessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)

Assessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD) William P. Saliski Jr. DO Montgomery Pulmonary Consultants Management of Stable COPD Pharmacotherapy Oxygen Smoking Cessation Vaccinations Rehabilitation Surgery Future Discussions Assessing Severity Staging

More information

What You Need to Know about Metered-Dose Inhalers and the HFA Propellant

What You Need to Know about Metered-Dose Inhalers and the HFA Propellant What You Need to Know about Metered- Inhalers and the HFA Propellant There are a number ways to deliver inhaled medication. They include: Metered-dose inhaler () Metered-dose inhaler with spacer/holding

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR

More information

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic

More information

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32

More information

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18 Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Position within the Organisation

Position within the Organisation ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September

More information

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS:

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: LOB: Respiratory Disorders Medi-Cal REVIEW HISTORY (MONTH/YEAR) 12/17,12/16, 5/15,

More information

Ambulatory Care. Ambulatory Care. Ila M. Harris, Pharm.D., FCCP, BCPS. University of Minnesota Minneapolis, Minnesota

Ambulatory Care. Ambulatory Care. Ila M. Harris, Pharm.D., FCCP, BCPS. University of Minnesota Minneapolis, Minnesota Ambulatory Care Ila M. Harris, Pharm.D., FCCP, BCPS University of Minnesota Minneapolis, Minnesota 1-165 Learning Objectives 1. Classify patients, assess control, and select and monitor appropriate acute

More information

Better Living with Obstructive Pulmonary Disease A Patient Guide

Better Living with Obstructive Pulmonary Disease A Patient Guide Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project

More information

Nucala (mepolizumab injection for subcutaneous use)

Nucala (mepolizumab injection for subcutaneous use) Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Orally Inhaled Corticosteroids to 2022

Orally Inhaled Corticosteroids to 2022 Greystone Research Associates 1+603-595-4340 April 2015 Orally Inhaled Corticosteroids to 2022 Drugs, Devices, Markets and Forecasts Contents A Comprehensive Market Analysis Report Scope & Overview 2 Table

More information

Wirral COPD Prescribing Guidelines

Wirral COPD Prescribing Guidelines Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed

More information